drugset / Trial / NCT05105412
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
Phase 1/2
Terminated
12 enrolled
National Health Research Institutes, Taiwan
Chang Gung Memorial Hospital · collabChina Medical University Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or refractory PTCL patients. Patients will be treated with the combination of lenalidomide and gemcitabine until disease progression, intolerable toxicity, or patient withdrawal.
Timeline
- Start
- 2022-06-15
- Primary completion
- 2024-03-30
- Completion
- 2024-03-30
Outcome
Outcome not reported
Stopped: “The resolution of DSMB”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 800 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |